Discovery and Clinical Development of Dutasteride, a Potent Dual 5α-Reductase Inhibitor
March 2006
in “
Current topics in medicinal chemistry
”
Studysummary This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on eurekaselect.com →